New approaches to the treatment of endometriosis

In: Reproductive Endocrinology · 2013 · pp. 36–42 · W3107768769
article OA: green CC0
🔓 Open OA copy View on OpenAlex
AI-generated summary by claude@2026-06, 2026-06-08

L-arginine (Tivortin) treatment in 64 women with endometriosis demonstrated impact on disease progression factors, suggesting its promise as a non-hormonal option for prevention and recurrence reduction.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The results of the study that involving 64 women with endometriosis have shown that the use in the treatment of L-arginine (the drug Tivortin) has a direct impact on the underlying factors that play role in the development and progression of endometriosis. It makes the use of non-hormonal drug promising in treatment of endometriosis andhas an important role in the prevention of its recurrence.

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

References (1)

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0 · commercial use OK